BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31455365)

  • 21. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.
    Choi H; Paeng JC; Kim DW; Lee JK; Park CM; Kang KW; Chung JK; Lee DS
    Lung Cancer; 2013 Mar; 79(3):242-7. PubMed ID: 23261227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics].
    Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J
    Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
    Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
    Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
    Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
    Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
    Choi CM; Kim MY; Hwang HJ; Lee JB; Kim WS
    Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
    Deng H; Liu C; Zhang G; Wang X; Liu Y
    Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
    Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W
    Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.
    Trejo Bittar HE; Luvison A; Miller C; Dacic S
    Histopathology; 2017 Aug; 71(2):269-277. PubMed ID: 28316074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
    Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
    Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India.
    Bal A; Singh N; Agarwal P; Das A; Behera D
    APMIS; 2016 Oct; 124(10):832-8. PubMed ID: 27500967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative analysis of immunohistochemistry and fluorescent
    Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
    Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Testing for EGFR Mutations and ALK Rearrangements in the Cytological Specimens From the Patients With Non-Small Cell Lung Cancer.
    Wang X; Chen S; Emerson RE; Wu HH; Cramer HM; Curless K; Chang HY; Zhang S; Randolph ML; Cheng L
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):119-124. PubMed ID: 30688675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
    Yip PY; Yu B; Cooper WA; Selinger CI; Ng CC; Kennedy CW; Kohonen-Corish MR; McCaughan BC; Trent RJ; Boyer MJ; Kench JG; Horvath LG; O'Toole SA
    J Thorac Oncol; 2013 Apr; 8(4):408-14. PubMed ID: 23392229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.
    Recondo G; Denninghoff V; Cuello MT; Lorente C; Greco M; De la Vega M; Avagnina A; Recondo G
    Medicina (B Aires); 2018; 78(6):385-394. PubMed ID: 30504104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathologic correlation and ALK rearrangement in adenocarcinoma of lung].
    Liu P; Wang C; Wu S; Gao J; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):241-5. PubMed ID: 24915814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.